Inflammatory bowel disease management during the COVID-19 outbreak: The 10 do's and don'ts from the ECCO-COVID Taskforce

J Crohns Colitis. 2020 Jul 29;jjaa160. doi: 10.1093/ecco-jcc/jjaa160. Online ahead of print.

F Magro 1, J-F Rahier 2, C Abeu 3, E MacMahon 4, A Hart 5, C J van der Woude 6, H Gordon 7, M Adamina 8, N Viget 9, S Vavricka 10, T Kucharzik 11, S Leone 12, B Siegmund 13, S Danese 14, L Peyrin-Biroulet 15 16


Author information


Our knowledge on COVID-19 is changing and evolving rapidly, with novel insights and recommendations, almost on a daily basis. It behooves the medical community to provide updated information on a regular basis, on best practice to facilitate optimal care of infected patients and appropriate advice for the general population. This is particularly important in the case of patients with chronic conditions, such as Inflammatory Bowel Disease (IBD). In this paper, we compiled the existing evidence on the impact of COVID-19 in IBD patients and provide guidance and on the most appropriate care to adopt during the pandemic. Our review highlighted that IBD, per se, is not a risk factor for COVID-19. However, all IBD patients with symptoms should be tested for SARS-CoV-2 and the procedures for disease management shall be carefully adapted: i) in SARS-CoV-2 positive IBD patients, medical treatments should be re-evaluated (with particular focus on corticosteroids) always with the purpose of treating active disease and maintaining remission; ii) non-urgent surgeries and endoscopic procedures should be postponed for all patients; iii) online consultancy should be implemented; and iv) hospitalization and surgery should be limited to life threatening situations.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.